# A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07281976/  
OnCo record `nct07281976` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in triple-negative breast cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT07281976 by Nanjing Leads Biolabs Co.,Ltd, with 220 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: LBL-024 for Injection, albumin-bound Paclitaxel injection and Toripalimab Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07281976
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT07281976: https://clinicaltrials.gov/study/NCT07281976

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07281976.json